Johnson & Johnson halts mid-stage study for dengue antiviral
by
Contributor since / Followers
Contributor since / Followers
1 day ago
koto_feja/E+ via Getty Images
- Johnson & Johnson (NYSE:JNJ) announced on Friday that it is discontinuing a Phase 2 field study for an antiviral treatment targeted at the prevention of dengue, a mosquito-borne viral infection that causes flu-like symptoms.
- The antiviral, mosnodenvir, formerly known as JNJ-1802, was tested in the trial for the prevention of dengue virus in people aged 18-65.
- The company said no safety issues were identified in the trial, and added that the decision to discontinue follows a strategic reprioritization of its R&D pipeline related to infectious diseases.
- The company noted it would announce the study’s efficacy results once the ongoing analysis of its final data is complete.
- In 2023, J&J (JNJ) advanced JNJ-1802 into mid-stage development following favorable safety data for the oral candidate in a Phase 1 first-in-human clinical study.